Nordic Nanovector stiger 15 prosent til 28,40 kroner etter publisering av en børsmelding med den klingende tittelen:«Pre-dosing NHL patients with HH1 anti-CD37 antibody before Betalutin® increases its pharmacokinetic exposure and reduces its haematological toxicity».Her finner du originalmeldingen:«ePoster to be presented at the 21st Congress of the European Hematology Association (9-12 June)Oslo, Norway, 10 June 2016Nordic Nanovector ASA (OSE: NANO) announces that pharmacokinetic analyses of a clinical study in patients with non-Hodgkin lymphoma (NHL) demonstrate that pre-dosing with the anti-CD37 antibody HH1, prior to injection with Betalutin® (177Lu-HH1) significantly increases the pharmacokinetic exposure of NHL tumour cells to Betalutin® (p < 0.001) while protecting against haematological side effects.The study, part of the ongoing Lymrit 37-01 Phase 1/2 trial of Betalutin® in NHL, evaluated 13 NHL patients who received different doses of Betalutin® either with or without HH1 pre-dosing. The analysis will be presented in an ePoster at the 21st Congress of the European Hematology Association (Copenhagen, Denmark, 9-12 June) by Dr Arne Kolstad, a senior consultant in medical oncology and radiotherapy at Oslo University Hospital, Radiumhospitalet and a member of Nordic Nanovector's Scientific Advisory Board. The poster is available here EHA 2016 ( -Reports/Poster%20EHA%202016%20-%20Copenhagen,%20DK.pdf)and at in the section: Product Info/Scientific Posters.Jostein Dahle, Nordic Nanovector CSO, commented: "The results presented in this poster continue to support our hypothesis that pre-dosing provides a protective effect on healthy tissues when used prior to Betalutin® treatment." The Lymrit 37-01 study is a Phase 1/2 open label, single injection ascending dose study investigating three dose levels of Betalutin® and different pre-dosing regimens in patients with relapsed NHL with the aim of identifying an optimal dose regimen to take into the Phase 2 PARADIGME study, which is expected to start in 2H 2017.»